LMO2 promotes angiogenesis probably by up-regulation of bFGF in endothelial cells: An implication of its pathophysiological role in infantile haemangioma

Histopathology

Volumn 57, Issue 4, 2010, Pages 622-632

  Sun, Zhi Jun ^a,b   Cai, Yu ^a,b   Chen, Gang ^a,b   Wang, Rong ^a   Jia, Jun ^a,b   Chen, Xin Ming ^b   Zheng, Li Wu ^c   Zhao, Yi Fang ^a,b  

^a Department of Oral and Maxillofacial Surgery   (China)

^b WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BFGF; Endothelial cells; Infantile haemangiomas; LMO2

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; LIM ONLY PROTEIN 2; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEMANGIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; UPREGULATION;

EID: 78650504772     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03676.x     Document Type: Article

References (34)

1. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv. Dermatol. 1997; 13; 375-423.
2. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr. Probl. Surg. 2000; 37; 517-584.
3. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 1994; 93; 2357-2364.
4. North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum. Pathol. 2000; 31; 11-22.
5. North PE, Mihm MC Jr. Histopathological diagnosis of infantile hemangiomas and vascular malformations. Facial Plast. Surg. Clin. North Am. 2001; 9; 505-524.
6. Mancini AJ, Smoller BR. Proliferation and apoptosis within juvenile capillary hemangiomas. Am. J. Dermatopathol. 1996; 18; 505-514.
7. Tan ST, Wallis RA, He Y, Davis PF. Mast cells and hemangioma. Plast. Reconstr. Surg. 2004; 113; 999-1011.
8. Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development 2003; 130; 6187-6199.
9. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991; 6; 1887-1893.
10. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc. Natl Acad. Sci. USA 2000; 97; 320-324.
11. Yamada Y, Pannell R, Forster A, Rabbitts TH. The LIM-domain protein Lmo2 is a key regulator of tumor angiogenesis: a new anti-angiogenesis drug target. Oncogene 2002; 21; 1309-1315.
12. Ma S, Guan XY, Beh PS et al. The significance of LMO2 expression in the progression of prostate cancer. J. Pathol. 2007; 211; 278-285.
13. Gratzinger D, Zhao S, West R et al. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am. J. Clin. Pathol. 2009; 131; 264-278.
14. Jia J, Bai Y, Fu K, Sun ZJ, Chen XM, Zhao YF. Expression of allograft inflammatory factor-1 and CD68 in haemangioma: implication in the progression of haemangioma. Br. J. Dermatol. 2008; 159; 811-819.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324; 1-8.
16. Djordjevic T, Pogrebniak A, BelAiba RS et al. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. Free Radic. Biol. Med. 2005; 38; 616-630.
17. Yamaguchi N, Anand-Apte B, Lee M et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999; 18; 4414-4423.
18. Cikos S, Bukovska A, Koppel J. Relative quantification of mRNA: comparison of methods currently used for real-time PCR data analysis. BMC Mol. Biol. 2007; 8; 113.
19. Li Q, Yu Y, Bischoff J, Mulliken JB, Olsen BR. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J. Pathol. 2003; 201; 296-302.
20. Dadras SS, North PE, Bertoncini J, Mihm MC, Detmar M. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod. Pathol. 2004; 17; 1068-1079.
21. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumors. Histopathology 2005; 46; 396-402.
22. Marler JJ, Fishman SJ, Kilroy SM et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 2005; 116; 38-45.
23. Goh SG, Calonje E. Cutaneous vascular tumors: an update. Histopathology 2008; 52; 661-673.
24. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1; 27-31.
25. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 1997; 22; 251-256.
26. Deleuze V, Chalhoub E, El-Hajj R et al. TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. Mol. Cell. Biol. 2007; 27; 2687-2697.
27. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86; 353-364.
28. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380; 435-439.
29. Risau W. Mechanisms of angiogenesis. Nature 1997; 386; 671-674.
30. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 1992; 189; 824-831.
31. Sun ZJ, Zhang L, Zhao YF. A postulated role for transcriptional regulator LMO2 in the proliferation and involution of hemangioma. Med. Hypotheses 2006; 67; 1230-1232.
32. Wang Q, Zhang M, Wang X et al. A novel transcript of the LMO2 gene, LMO2-c, is regulated by GATA-1 and PU.1 and encodes an antagonist of LMO2. Leukemia 2007; 21; 1015-1025.
33. Nam CH, Lobato MN, Appert A, Drynan LF, Tanaka T, Rabbitts TH. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions. Oncogene 2008; 27; 4962-4968.
34. Felli N, Pedini F, Romania P et al. MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica 2009; 94; 479-486.